RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Biomarin Pharmaceutical Stock

Biomarin Pharmaceutical P/E 2024

Biomarin Pharmaceutical P/E

35.3

Ticker

BMRN

ISIN

US09061G1013

WKN

924801

As of Nov 8, 2024, Biomarin Pharmaceutical's P/E ratio was 35.3, a -65% change from the 100.87 P/E ratio recorded in the previous year.

The Biomarin Pharmaceutical P/E history

Biomarin Pharmaceutical Aktienanalyse

What does Biomarin Pharmaceutical do?

Biomarin Pharmaceutical Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare genetic diseases. The company was founded in 1997 and is headquartered in San Rafael, California. Biomarin Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Biomarin Pharmaceutical revenue by segment

In the annual report of the Biomarin Pharmaceutical share (US09061G1013, 924801, BMRN), it breaks down its revenues into 1 segments: 1. Development & Commercialization of Innovative Therapies. The Biomarin Pharmaceutical stock (WKN: 924801, ISIN: US09061G1013, Ticker Symbol: BMRN) is a leading investment for investors interested in participating in the Health Care sector.

  • 100 % Development & Commercialization of Innovative Therapies

P/E Details

Deciphering Biomarin Pharmaceutical's P/E Ratio

The Price to Earnings (P/E) Ratio of Biomarin Pharmaceutical is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Biomarin Pharmaceutical's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Biomarin Pharmaceutical is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Biomarin Pharmaceutical’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Biomarin Pharmaceutical stock

What is the price-to-earnings ratio of Biomarin Pharmaceutical?

The price-earnings ratio of Biomarin Pharmaceutical is currently 35.3.

How has the price-earnings ratio of Biomarin Pharmaceutical changed compared to last year?

The price-to-earnings ratio of Biomarin Pharmaceutical has increased by -65% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Biomarin Pharmaceutical high compared to other companies?

Yes, the price-to-earnings ratio of Biomarin Pharmaceutical is high compared to other companies.

How does an increase in the price-earnings ratio of Biomarin Pharmaceutical affect the company?

An increase in the price-earnings ratio of Biomarin Pharmaceutical would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Biomarin Pharmaceutical affect the company?

A decrease in the price-earnings ratio of Biomarin Pharmaceutical would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Biomarin Pharmaceutical?

Some factors that influence the price-earnings ratio of Biomarin Pharmaceutical are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Biomarin Pharmaceutical pay?

Over the past 12 months, Biomarin Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biomarin Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Biomarin Pharmaceutical?

The current dividend yield of Biomarin Pharmaceutical is .

When does Biomarin Pharmaceutical pay dividends?

Biomarin Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biomarin Pharmaceutical?

Biomarin Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Biomarin Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biomarin Pharmaceutical located?

Biomarin Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biomarin Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biomarin Pharmaceutical from 11/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.

When did Biomarin Pharmaceutical pay the last dividend?

The last dividend was paid out on 11/8/2024.

What was the dividend of Biomarin Pharmaceutical in the year 2023?

In the year 2023, Biomarin Pharmaceutical distributed 0 USD as dividends.

In which currency does Biomarin Pharmaceutical pay out the dividend?

The dividends of Biomarin Pharmaceutical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Biomarin Pharmaceutical stock can be added to a savings plan with the following providers: Consorsbank

Andere Kennzahlen von Biomarin Pharmaceutical

Our stock analysis for Biomarin Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomarin Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.